Ligand Pharmaceuticals received a rating increase and price target raise from Bank of America on August 5, while the company also listed its stock on Nasdaq.
1 report, 1 independent
Updated Aug 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ligand Pharmaceuticals received a rating increase and price target raise from Bank of America on August 5, while the company also listed its stock on Nasdaq.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Ligand Pharmaceuticals
biopharmaceutical company based out of La Jolla, California
-
Bank of America
American multinational banking and financial services corporation
Related events
- Bank of America boosted its price target and gave a buy rating for Guardian Pharmacy Services, Inc. on September 15, 2026. Truist Financial also boosted its target price and gave a buy rating on the same day.
- BlackRock raised its target price and gave a buy rating for Bank of America.
- Vera Therapeutics Inc. stock traded on the Nasdaq exchange on August 4, 2026, and received analyst ratings from Bank of America.
- Bank of America raised its rating and price target for a company due to promising CPU opportunities.
- Morgan Stanley and Bank of America raised price targets on NetApp shares, with MarketBeat reporting the consensus rating.